Glatiramer Acetate
|
Immune-modulator
|
HLA-DRB1
|
Multiple sclerosis
|
Fluoxetine
|
SSRI
|
0.001
|
Tenosynovitis (6); Skin hypertrophy (5); Tongue discolouration (5); Alcohol intolerance (4); Circumoral paresthesia (4); Dental caries (4); Depressive type psychosis (4); Rheumatoid arthritis (4); Salivary gland enlargement (4); Urethritis (4)
|
Paroxetine
|
SSRI
|
0.006
|
Fluvoxamine
|
SSRI
|
0.001
|
Selegiline
|
MAO-B inhibitor
|
<0.001
|
Mirtazapine
|
5HT & α2-adrenergic receptor antagonist
|
<0.001
|
Lenalidomide
|
Immune-modulator
|
TNF-α
|
Multiple myeloma; Myelodysplastic syndromes
|
Pramipexole
|
Non-ergoline dopamine agonist
|
0.019
|
Chronic obstructive pulmonary disease (3); Diverticulitis (3); Ear infection (3) Prostate cancer (3)
|
Ustekinumab
|
Immune-modulator
|
Interleukin 12/23
|
Plaque psoriasis; Psoriatic arthritis
| | |
0.002
| |
Pimecrolimus
|
Immune-modulator
|
Calcineurin
|
Atopic dermatitis
|
<0.001
|
Siltuximab
|
Immune-modulator
|
Interleukin 6
|
Castleman’s disease
|
<0.001
|
Rapamycin
|
Immune-modulator
|
Mammalian target of rapamycin (mTOR)
|
Rejection in organ transplant
|
Selegiline
|
MAO-B inhibitor
|
0.016
| |
Montelukast
|
Immune-modulator
|
Cysteinyl leukotriene receptor 1 (CYSLTR1)
|
Asthma; Seasonal allergies
|
Bupropion
|
Dopamine & norepinephrine reuptake inhibitor
|
0.011
| |
Naproxen
|
Anti-inflammatory; Analgesic
|
COX-1/2
|
Inflammations; Pain
|
Paroxetine
|
SSRI
|
0.006
|
Bleeding time prolonged (4); Retinal haemorrhage (4); Fever chills (4); Pyuria (4); Keratoconjunctivitis (3); WBC abnormal NOS (3); Tenosynovitis (3) ; Urethritis (3); Deficiency anaemia (3); Diarrhoea haemorrhagic (3); Electroencephalogram abnormal (3); Enteritis (3); Iron deficiency (3); Iron deficiency anaemia (3)
|
Ketoprofen
| | | |
Fluoxetine
|
SSRI
|
0.003
| |
Flurbiprofen
|
Paroxetine
|
SSRI
|
<0.001
|
| | | |
Fluoxetine
|
SSRI
|
<0.001
| |
Diclofenac
| | | |
Nefazodone
|
5HT receptor antagonist
|
0.037
| |
Rofecoxib
| |
COX-2
| |
Duloxetine
|
SNRI
|
0.029
| |
Meloxicam
|
Clomipramine
|
Non-selective monoamine reuptake inhibitor (TCA)
|
0.031
| |
Valdecoxib
|
Sertraline
|
SSRI
|
0.015
| |
Fludrocortisone
|
Anti-inflammatory
|
Mineralocorticoid receptor/Glucocorticoid receptor
|
Addison’s disease/salt-losing adrenogenital syndrome
|
Lithium
|
Other
|
0.004
|
Benign intracranial hypertension (4); Exophthalmos (4); Papilloedema (4); Pseudotumor (4)
|
Cortisone
|
Glucocorticoid receptor
|
Inflammations; Pain
|
0.005
|
Hydrocortisone
|
Glucocorticoid receptor
|
Severe allergic reactions; Inflammations
|
0.001
|
Hydrocortisone 17-butyrate
|
Glucocorticoid receptor (NR3C1)
|
Skin irritations
|
Venlafaxine
|
SNRI
|
0.017
|
Miliaria (5); Skin atrophy (5); Skin striae (5)
|
Clocortolone
|
0.012
|
Alclometasone
|
0.01
|
Halcinonide
|
NR3C1 and SMO
|
0.026
|